Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Use of Robot in Prostatectomy to Be Approved as Senshin-iryo
September 27, 2010
- Toyobo to Strengthen Bulk Manufacturing & Contract R&D for Biopharmaceuticals
September 27, 2010
- 29 Ex-Korosho Officials Employed by 15 Drug Firms
September 27, 2010
- Mochida Applies for Escitalopram in Japan
September 27, 2010
- LabCorp to Acquire Genzyme Genetics for US$925 Mil. in Cash
September 27, 2010
- Fingolimod Approved in Russia: Novartis
September 27, 2010
- E Keppra to Expand Market for Anti-epileptic Agents: Otsuka, UCB
September 27, 2010
- 5-Aminolevulinic Acid HCl Designated as Orphan Drug
September 27, 2010
- JCR Completes Manufacturing Facility for EPO Biosimilar
September 27, 2010
- Symposiasts Call for Unification of Clinical Research, Trials
September 27, 2010
- Novartis to Keep Weighted Average Invoice Price Unchanged: Mr Mitani
September 27, 2010
- Two GM Mice Lost at Kyowa Kirin's Research Center
September 27, 2010
- Tadaharu Goto Appointed New JPMA Director General
September 27, 2010
- Eisai to Apply for Eszopiclone within FY2010
September 27, 2010
- Mediceo Encourages Its MSs to Take Exam for MR Certification
September 27, 2010
- Agensys Begins PI for AGS-16M8F for RCC
September 27, 2010
- Emerging Countries Drive Global Drug Industry: Ms Chui of IMS
September 27, 2010
- Abstract of PII for CBP501 Presented at IMIG2010: CanBas
September 27, 2010
- Prof. Morishita Calls For Creation of Environment Friendly to Bioventures
September 27, 2010
- 30% Market Share for Generics Unlikely to Be Achieved: Mr Mitsuhara
September 27, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…